154 related articles for article (PubMed ID: 31736321)
1. Ceftriaxone versus ampicillin/sulbactam for the treatment of aspiration-associated pneumonia in adults.
Hasegawa S; Shiraishi A; Yaegashi M; Hosokawa N; Morimoto K; Mori T
J Comp Eff Res; 2019 Nov; 8(15):1275-1284. PubMed ID: 31736321
[No Abstract] [Full Text] [Related]
2. Comparison of ceftriaxone plus macrolide and ampicillin/sulbactam plus macrolide in treatment for patients with community-acquired pneumonia without risk factors for aspiration: an open-label, quasi-randomized, controlled trial.
Hamao N; Ito I; Konishi S; Tanabe N; Shirata M; Oi I; Tsukino M; Matsumoto H; Yasutomo Y; Kadowaki S; Hirai T
BMC Pulm Med; 2020 Jun; 20(1):160. PubMed ID: 32503515
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of azithromycin in aspiration pneumonia: a prospective observational study.
Marumo S; Teranishi T; Higami Y; Koshimo Y; Kiyokawa H; Kato M
BMC Infect Dis; 2014 Dec; 14():685. PubMed ID: 25491126
[TBL] [Abstract][Full Text] [Related]
4. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae.
Tsukada H; Sakai K; Cho H; Kimura Y; Tetsuka T; Nakajima H; Ito K
J Infect Chemother; 2012 Oct; 18(5):715-21. PubMed ID: 22460828
[TBL] [Abstract][Full Text] [Related]
5. Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia: A propensity score matching analysis.
Asai N; Suematsu H; Ohashi W; Shibata Y; Sakanashi D; Kato H; Shiota A; Watanabe H; Hagihara M; Koizumi Y; Yamagishi Y; Mikamo H
J Infect Chemother; 2021 Oct; 27(10):1465-1470. PubMed ID: 34158237
[TBL] [Abstract][Full Text] [Related]
6. Ampicillin + sulbactam vs clindamycin +/- cephalosporin for the treatment of aspiration pneumonia and primary lung abscess.
Allewelt M; Schüler P; Bölcskei PL; Mauch H; Lode H;
Clin Microbiol Infect; 2004 Feb; 10(2):163-70. PubMed ID: 14759242
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients.
Kadowaki M; Demura Y; Mizuno S; Uesaka D; Ameshima S; Miyamori I; Ishizaki T
Chest; 2005 Apr; 127(4):1276-82. PubMed ID: 15821205
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic, bacteriological and clinical studies of sulbactam/ampicillin in pediatric patients].
Motohiro T; Sakata Y; Oda K; Aramaki M; Tanaka K; Koga T; Shimada Y; Fujimoto T; Yamashita F; Sakamoto H
Jpn J Antibiot; 1989 Mar; 42(3):773-90. PubMed ID: 2664252
[TBL] [Abstract][Full Text] [Related]
9. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam.
Carmeli Y; Castro J; Eliopoulos GM; Samore MH
Antimicrob Agents Chemother; 2001 Jan; 45(1):275-9. PubMed ID: 11120977
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial Prophylaxis With Ampicillin-sulbactam Compared With Cefazolin for Esophagectomy: Nationwide Inpatient Database Study in Japan.
Hirano Y; Konishi T; Kaneko H; Itoh H; Matsuda S; Kawakubo H; Uda K; Matsui H; Fushimi K; Daiko H; Itano O; Yasunaga H; Kitagawa Y
Ann Surg; 2024 Apr; 279(4):640-647. PubMed ID: 38099477
[TBL] [Abstract][Full Text] [Related]
11. Ampicillin/sulbactam versus cefazolin plus aminoglycosides for antimicrobial prophylaxis in management of Gustilo type IIIA open fractures: A retrospective cohort study.
Takahara S; Tokura T; Nishida R; Uefuji A; Ichimura K; Nishihara H; Aoki K; Takayama H; Nakagawa N; Harada T
Injury; 2022 Apr; 53(4):1517-1522. PubMed ID: 35090733
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Kohno S; Tateda K; Mikamo H; Kadota J; Niki Y; Itamura R
J Infect Chemother; 2015 Mar; 21(3):182-8. PubMed ID: 25533886
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic and clinical studies on sulbactam/ampicillin in children].
Hattori K; Higashino H; Kobayashi T; Yamamoto C; Nobori U; Nakamura Y; Satou Y; Kurokawa H; Nogi S; Kobayashi Y
Jpn J Antibiot; 1989 Mar; 42(3):701-17. PubMed ID: 2746850
[TBL] [Abstract][Full Text] [Related]
14. [Studies on sulbactam/ampicillin in the field of pediatrics].
Nakamura H; Miyazu M; Kasai K; Iwai N; Taneda Y
Jpn J Antibiot; 1989 Mar; 42(3):662-74. PubMed ID: 2664250
[TBL] [Abstract][Full Text] [Related]
15. Ampicillin- and ampicillin/sulbactam-resistant Escherichia coli infection in a neonatal intensive care unit in Japan.
Saida K; Ito Y; Shima Y; Kasuga E; Kusakari M; Miyosawa Y; Baba A
Pediatr Int; 2016 Jun; 58(6):537-9. PubMed ID: 27322865
[TBL] [Abstract][Full Text] [Related]
16. Risk evaluation of ampicillin/sulbactam-induced liver injury based on albumin-bilirubin score.
Ooi H; Asai Y; Sato Y
J Infect Chemother; 2023 Sep; 29(9):900-904. PubMed ID: 37301371
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind comparison of ampicillin/sulbactam and ceftriaxone in the prevention of surgical-site infections after neurosurgery.
Zhu XL; Wong WK; Yeung WM; Mo P; Tsang CS; Pang KH; Po YC; Aung TH
Clin Ther; 2001 Aug; 23(8):1281-91. PubMed ID: 11558864
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of sulbactam/ampicillin in children].
Ito S; Mayumi M; Ito M; Mikawa H
Jpn J Antibiot; 1989 Mar; 42(3):675-85. PubMed ID: 2664251
[TBL] [Abstract][Full Text] [Related]
19. [Laboratory and clinical studies of sulbactam/ampicillin in pediatric field].
Nishimura T; Tabuki K; Aoki S; Sugita K; Takagi M
Jpn J Antibiot; 1989 Mar; 42(3):687-700. PubMed ID: 2746849
[TBL] [Abstract][Full Text] [Related]
20. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly.
Okimoto N; Kurihara T; Honda N; Asaoka N; Fujita K; Ohba H; Nakamura J
J Infect Chemother; 2003 Jun; 9(2):183-6. PubMed ID: 12825120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
